BTAI BioXcel Therapeutics Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics (BTAI) leverages AI to adapt neuropsychiatric drugs, ensuring a steady inflow of funds and sustainable FCF. The quarterly EPS trajectory confirms this stability, where the value of 79.90 aligns with the current metric. The development of dementia treatments in the US and the modernization of laboratory facilities guarantee the continuity of production cycles and the high efficiency of research systems.

BioXcel Therapeutics, Inc. (BTAI) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 09/19/2026

Analytical breakdowns for BioXcel Therapeutics

- share price and consensus valuation forecast:
Stock Quotes BioXcel Therapeutics, Inc.|BTAI - Analyst Consensus Forecast
- company stock capitalization data:
Market Value BioXcel|BTAI - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share BioXcel Therapeutics|BTAI - Total Stockholders' Equity|Market Value to Book Value Ratio bioxceltherapeutics.com|BTAI - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity BioXcel Therapeutics|BTAI - Long-Term Liabilities to Capital|Short-Term Debt to Capital BioXcel Therapeutics|BTAI - Company Total Indebtedness|Debt to Book Value BioXcel|BTAI - Long-Term Debt|Company Short-Term Debts BioXcel Therapeutics|Quick Ratio bioxceltherapeutics.com
- earnings and market multiples details:
BTAI - Net Financial Result|Expected Profit BioXcel Therapeutics|BTAI - Market Cap to Earnings|Projected Price to Earnings BioXcel|BTAI - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple BioXcel|BTAI - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) BioXcel Therapeutics|BTAI - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bioxceltherapeutics.com|BTAI - Earnings per share growth in current year|Expected earnings per share growth for next year BioXcel Therapeutics
- sales volume and revenue indicators:
BTAI - Company Sales Revenue|Company Future Sales Volume BioXcel Therapeutics, Inc.|BTAI - Market Cap to Sales Volume|Forward P/S Multiple BioXcel
Fundamental company analysis:BioXcel Therapeutics, Inc., BTAI
Manufactured product of BioXcel Therapeutics Corp

For BioXcel Therapeutics (BTAI), which utilizes AI in neurology, the commercialization of drugs is transforming operational risks into a steady profit stream. Analyzing the history of quarterly EPS changes allows for an assessment of net income per share dynamics, identifying business resilience to shocks and the risk of overpaying for the asset by comparing the current growth rate with long-term fundamental trends.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals plc) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Inc. (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics Corp|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Pharmaceuticals (CNTA)|DYN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Edgewise Therapeutics, Inc. EWTX|Rapport Therapeutics Inc - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Corp|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year larimartx.com LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Entrada Therapeutics Inc. TRDA|Quarterly EPS earnings growth PTHS|Year-over-year earnings per share growth for the last twelve months MNOV (medicinova.com)|Quarterly EPS earnings growth SER (Serina Therapeutics, Inc.)|Year-over-year net earnings per share change for the last twelve months ProMIS Neurosciences Inc. (PMN)|APUS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma|NLSP (nlspharma.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|HUGE (FSD Pharma Inc.) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months reatapharma.com (RETA)